Cell sensitivity assays: The ATP-based tumor chemosensitivity assay

Methods in Molecular Biology

Volumn 731, Issue , 2011, Pages 247-257

  Glaysher, Sharon ^a   Cree, Ian A ^a  

^a NONE

Author keywords

ATP; Cell line; Chemoresistance; Chemosensitivity; Combination; Primary cell culture; Selective medium

Indexed keywords

ADENOSINE TRIPHOSPHATE; DETERGENT; LUCIFERASE; LUCIFERIN; POLYPROPYLENE; CELL EXTRACT;

ARTICLE; ATP BASED TUMOR CHEMOSENSITIVITY ASSAY; CELL AGGREGATION; CELL ASSAY; CELL SUSPENSION; CELL TYPE; CHEMOSENSITIVITY; CONTINUOUS CULTURE; CULTURE MEDIUM; ENZYME ASSAY; EXTRACTION; FREEZE THAWING; INCUBATION TIME; LUMINESCENCE; PRIORITY JOURNAL; TUMOR SPHEROID; CALIBRATION; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; MICROARRAY ANALYSIS; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; CALIBRATION; CELL EXTRACTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICROARRAY ANALYSIS;

EID: 84934435702     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-80-5_21     Document Type: Article

References (25)

1. Hunter, E. M., Sutherland, L. A., Cree, I. A., Dewar, J. A., Preece, P. E., Wood, R. A., Linder, D., and Andreotti, P. E. (1993) Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphos-phate (ATP) chemiluminescence assay, Eur J Surg Oncol 19, 242-249.
2. Andreotti, P. E., Cree, I. A., Kurbacher, C. M., Hartmann, D. M., Linder, D., Harel, G., Gleiberman, I., Caruso, P. A., Ricks, S. H., Untch, M., Sartori, D.C. and Bruckner H. (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphos-phate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma, Cancer Res 55, 5276-5282.
3. Cree, I. A., Kurbacher, C. M., Untch, M., Sutherland, L. A., Hunter, E. M., Subedi, A. M., James, E. A., Dewar, J. A., Preece, P. E., Andreotti, P. E., and Bruckner, H. W. (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemo-sensitivity, Anticancer Drugs 7, 630-635.
4. Sharma, S., Neale, M. H., Di Nicolantonio, F., Knight, L. A., Whitehouse, P. A., Mercer, S. J., Higgins, B. R., Lamont, A., Osborne, R., Hindley, A. C., Kurbacher, C. M., and Cree, I. A. (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma, BMC Cancer 3, 19.
5. Cree, I. A., Kurbacher, C. M., Lamont, A., Hindley, A. C., and Love, S. (2007) A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer, Anticancer Drugs 18, 1093-1101.
6. Konecny, G., Crohns, C., Pegram, M., Felber, M., Lude, S., Kurbacher, C., Cree, I. A., Hepp, H., and Untch, M. (2000) Correlation of drug response with the ATP tumorchemo-sensitivity assay in primary FIGO stage III ovarian cancer, Gynecol Oncol 77, 258-263.
7. Ugurel, S., Schadendorf, D., Pfohler, C., Neuber, K., Thoelke, A., Ulrich, J., Hauschild, A., Spieth, K., Kaatz, M., Rittgen, W., Delorme, S., Tilgen, W., and Reinhold, U. (2006) In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group, Clin Cancer Res 12, 5454-5463.
8. Kurbacher, C. M., and Cree, I. A. (2005) Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements, Methods Mol Med 110, 101-120.
9. Kurbacher, C. M., Bruckner, H. W., Cree, I. A., Kurbacher, J. A., Wilhelm, L., Poch, G., Indefrei, D., Mallmann, P., and Andreotti, P. E. (1997) Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial, Clin Cancer Res 3, 1527-1533.
10. Myatt, N., Cree, I. A., Kurbacher, C. M., Foss, A. J., Hungerford, J. L., and Plowman, P. N. (1997) The ex vivo chemosensitivity profle of choroidal melanoma, Anticancer Drugs 8, 756-762.
11. Neale, M. H., Myatt, N., Cree, I. A., Kurbacher, C. M., Foss, A. J., Hungerford, J. L., and Plowman, P. N. (1999) Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside, Br J Cancer 79, 1487-1493.
12. Corrie, P. G., Shaw, J., Spanswick, V. J., Sehmbi, R., Jonson, A., Mayer, A., Bulusu, R., Hartley, J. A., and Cree, I. A. (2005) Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients, Br J Cancer 92, 1997-2003.
13. Pfohler, C., Cree, I. A., Ugurel, S., Kuwert, C., Haass, N., Neuber, K., Hengge, U., Corrie, P. G., Zutt, M., Tilgen, W., and Reinhold, U. (2003) Treosulfan and gemcit-abine in metastatic uveal melanoma patients: results of a multicenter feasibility study, Anticancer Drugs 14, 337-340.
14. Di Nicolantonio, F., Neale, M. H., Knight, L. A., Lamont, A., Skailes, G. E., Osborne, R. J., Allerton, R., Kurbacher, C. M., and Cree, I. A. (2002) Use of an ATP-based chemosensi-tivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer, Anticancer Drugs 13, 625-630.
15. Knight, L. A., Di Nicolantonio, F., Whitehouse, P., Mercer, S., Sharma, S., Glaysher, S., Johnson, P., and Cree, I. A. (2004) The in vitro effect of geftinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours, BMC Cancer 4, 83.
16. Knight, L. A., Di Nicolantonio, F., Whitehouse, P. A., Mercer, S. J., Sharma, S., Glaysher, S., Hungerford, J. L., Hurren, J., Lamont, A., and Cree, I. A. (2006) The effect of imatinib mesylate (Glivec) on human tumor-derived cells, Anticancer Drugs 17, 649-655.
17. Di Nicolantonio, F., Knight, L. A., Glaysher, S., Whitehouse, P. A., Mercer, S. J., Sharma, S., Mills, L., Prin, A., Johnson, P., Charlton, P. A., Norris, D., and Cree, I. A. (2004) Ex vivo reversal of chemoresistance by tariquidar (XR9576), Anticancer Drugs 15, 861-869.
18. Knight, L. A., Kurbacher, C. M., Glaysher, S., Fernando, A., Reichelt, R., Dexel, S., Reinhold, U., and Cree, I. A. (2009) Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay, BMC Cancer 9, 38.
19. Fernando, A., Glaysher, S., Conroy, M., Pekalski, M., Smith, J., Knight, L. A., Di Nicolantonio, F., and Cree, I. A. (2006) Effect of culture conditions on the chemosen-sitivity of ovarian cancer cell lines, Anticancer Drugs 17, 913-919.
20. Di Nicolantonio, F., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Glaysher, S., Di Palma, S., Johnson, P., Somers, S. S., Toh, S., Higgins, B., Lamont, A., Gulliford, T., Hurren, J., Yiangou, C., and Cree, I. A. (2005) Cancer cell adaptation to chemotherapy, BMC Cancer 5, 78.
21. Mercer, S. J., Di Nicolantonio, F., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Bhandari, P., Somers, S. S., Toh, S. K., and Cree, I. A. (2005) Rapid up-regulation of cyclooxygenase-2 by 5-fuo-rouracil in human solid tumors, Anticancer Drugs 16, 495-500.
22. Glaysher, S., Yiannakis, D., Gabriel, F. G., Johnson, P., Polak, M. E., Knight, L. A., Goldthorpe, Z., Peregrin, K., Gyi, M., Modi, P., Rahamim, J., Smith, M. E., Amer, K., Addis, B., Poole, M., Narayanan, A., Gulliford, T. J., Andreotti, P. E., and Cree, I. A. (2009) Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC), BMC Cancer 9, 300.
23. Hunter, E. M., Sutherland, L. A., Cree, I. A., Subedi, A. M., Hartmann, D., Linder, D., and Andreotti, P. E. (1994) The infuence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay, Anti-cancer drugs 5, 171-176.
24. Palmgren, J. J., Monkkonen, J., Korjamo, T., Hassinen, A., and Auriola, S. (2006) Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions, Eur J Pharm Biopharm 64, 369-378.
25. Di, S., Li-Fen, H., and Jessie, L. S. A. (1996) Binding of taxol to plastic and glass containers and protein under in vitro conditions, Journal of Pharmaceutical Sciences 85, 29-31.